Exelixis, Inc.

Good day, ladies and gentlemen, and welcome to the Exxon Liquors fourth quarter and four-year 2021 financial results conference call. My name is Tawanda, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. You may begin. Thank you.

Thank you, Tawanda, and thank you all for joining us for the Exalexis fourth quarter 2021 and full year 2021 financial results conference call. Joining me on today's call are Mike Morrissey, our president and CEO, Chris Senner, our chief financial officer, TJ Haley, our executive vice president of commercial, Vicki Goodman, our chief medical officer, and Peter Lamb, our chief scientific officer, who will together review our progress for the fourth quarter 2021. 2021, ended December 31st, 2021. During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website, for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results. During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of cost associated with discovery, product development, business development, and commercialization activities. And with that, I will turn the call over to Mike.

All right. Thank you, Susan, and thanks to everyone for joining us on the call today. ExoLuxus had a strong fourth quarter and full year 2021 across all components of our enterprise, as we continue to grow the Cobb's Antidote business and advance a diversified and growing pipeline of clinical and discovery programs. We'll keep our prepared remarks short today, as we recently gave a detailed update to start 2022 at the J.P. Morgan Healthcare Conference in January. Key topics we'll focus on today include, first, the Cobb Medics business continues to grow and fuel the investment in advancing our portfolio of next-generation therapies for oncology. Hub-O-Medics maintained its status as the leading TKI for RCC and surpassed the billion-dollar net product revenue threshold in the U.S. in 2021 with a 45% year-over-year growth compared to 2020. Second, we expect our development team, now led by Vicki Goodman, to grow in size, scope, and stature in 2022 and beyond with the build-out of Exalexis East, complementing our extensive development, breadth, and depth in Alameda. 2022 could be a year of significant portfolio growth with a focus on expanding potential indications for CAVO with numerous expected top-line results and advancing our important pipeline molecules XL092, XB002, and XL102, including the initiation of the pivotal trial program for XL092. Third and finally, our drug discovery network of internal and collaborative efforts across both small molecule and biologic platforms continues to advance at a rapid pace with the selection of up to five new development candidates expected in 2022. Business development activities remain a core component of this strategy. We expect to bring additional collaborations forward, including the potential for clinical assets where we have increased conviction from both a clinical and commercial perspective. With that, please see our press release issued an hour ago for our fourth quarter financial results. and an extensive list of key corporate milestones achieved in the quarter. I'll now turn the call over to Chris, who will review our fourth quarter and full year 2021 financial results.